Free Alerts   Login
Health Care › Pharmaceutical Preparations

EBS Stock Price Correlated With Emergent BioSolutions Financials

EBS Stock Price vs. Quarterly
EBS
Income Statement
Cash Flow
Balance Sheet

EBS Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

EBS Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

EBS Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock.
9,399,197 sh
963,517 sh
11%
$22,557
-$6,125
Vanguard Group
2,974,638 sh
328,272 sh
12%
$7,139
-$1,858
Charles Schwab Investment Management
2,873,984 sh
1,312,934 sh
84%
$6,898
$1,590
Millennium Management
2,095,662 sh
-1,570,717 sh
-43%
$5,030
-$7,436
Hotchkis & Wiley Capital Management
1,647,243 sh
-781,247 sh
-32%
$3,953
-$4,304
Morgan Stanley
1,235,356 sh
625,316 sh
103%
$2,965
$891
D. E. Shaw & Co..
1,186,552 sh
250,034 sh
27%
$2,848
-$336
Geode Capital Management
1,097,219 sh
78,184 sh
8%
$2,634
-$831
Two Sigma Advisers, Lp
1,087,700 sh
20,400 sh
2%
$2,610
-$1,019
State Street
1,062,951 sh
-69,004 sh
-6%
$2,551
-$1,298
Jacobs Levy Equity Management
1,043,284 sh
-202,736 sh
-16%
$2,504
-$1,732
Two Sigma Investments, Lp
1,038,600 sh
2,624 sh
0%
$2,493
-$1,029
Prescott Group Capital Management, L.L.C.
853,349 sh
554,162 sh
185%
$2,048
$1,031
Assenagon Asset Management S.A.
834,372 sh
651,480 sh
356%
$2,002
$1,380
Goldman Sachs Group
751,887 sh
93,301 sh
14%
$1,804
-$436
Dimensional Fund Advisors
658,220 sh
-143,383 sh
-18%
$1,579
-$1,147
Qube Research & Technologies
621,177 sh
621,177 sh
NEW
$1,491
$1,491
Bridgeway Capital Management
616,457 sh
-252,148 sh
-29%
$1,479
-$1,474
Renaissance Technologies
547,300 sh
547,300 sh
NEW
$1
$1
Aqr Capital Management
513,416 sh
334,298 sh
187%
$1,232
$627
COMPANY PROFILE
Business Overview

Emergent BioSolutions Inc. (the Company or Emergent) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (PHTs). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (CDMO) services portfolio.

The Company is focused on the following five distinct PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases (EID); travel health; emerging health crises; and acute/emergency care. The Company has a product portfolio of eleven products (vaccines, therapeutics, and drug-device combination products) that contribute a substantial portion of its revenue. The Company has one product candidate that is procured under special circumstances by the U.S. government (USG), although it is not approved by the U.S. Food and Drug Administration (FDA). The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include a Government - Medical Countermeasures (MCM) business line, a Commercial business line and a Services line focused on CDMO.

The Company's products and services include:

Government - MCM Products

▪ AV7909 ® , is a procured product candidate being developed as a next generation anthrax vaccine for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure. The USG has largely switched from procuring BioThrax to AV7909 for the Strategic National Stockpile (SNS) prior to its approval by the FDA; and

▪ BioThrax ® , the only vaccine licensed by the FDA, for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;

▪ ACAM2000 ® , the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;

▪ BAT ® , the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of botulism; and;

▪ CNJ-016 ® , also referred to as VIGIV, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination.

▪ Raxibacumab injection, a fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;

▪ Anthrasil ® , the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;

▪ RSDL ® , the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas, and T-2 toxin.

▪ Trobigard ® atropine sulfate, obidoxime chloride AUTO-INJECTOR, is a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA, but it is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure.

Commercial Products

▪ NARCAN ® (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression; Recently, the Company licensed an authorized generic of naloxone nasal spray to Sandoz; and

▪ Vaxchora ® (Cholera Vaccine, Live, Oral), the only single-dose oral vaccine licensed by the FDA and the European Medicines Agency (EMA) for the prevention of cholera; and

▪ Vivotif ® (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever.

Services - Contract Development and Manufacturing

The Company's services line focused on CDMO offerings cover development service

Free historical financial statements for Emergent BioSolutions Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 48 quarters since 2012. Compare with EBS stock chart to see long term trends.

Data imported from Emergent BioSolutions Inc. SEC filings. Check original filings before making any investment decision.